Patents by Inventor Franciscus Johannes Ignatius Nagel

Franciscus Johannes Ignatius Nagel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Manufacturing Methods To Control C-Terminal Lysine, Galactose And Sialic Acid Content In Recombinant Proteins
    Publication number: 20220089712
    Abstract: Provided herein is a method for producing an antibody, such as an anti-TNF? antibody (e.g., infliximab) having a C-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with DNA encoding the antibody in a culture medium comprising at least 0.5 ?M zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody.
    Type: Application
    Filed: September 29, 2021
    Publication date: March 24, 2022
    Inventors: Marcel Flikweert, Charles Goochee, Francis C. Maslanka, Franciscus Johannes Ignatius Nagel, James R. Ryland, Eugene Schaefer
  • Manufacturing methods to control C-terminal lysine, galactose and sialic acid content in recombinant proteins
    Patent number: 11149085
    Abstract: Provided herein is a method for producing an antibody, such as an anti-TNF? antibody (e.g., infliximab) having a C-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with DNA encoding the antibody in a culture medium comprising at least 0.5 ?M zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: October 19, 2021
    Assignees: JANSSEN BIOTECH, INC., JANSSEN BIOLOGICS B.V.
    Inventors: Marcel Flikweert, Charles Goochee, Francis C. Maslanka, Franciscus Johannes Ignatius Nagel, James R. Ryland, Eugene Schaefer
  • Manufacturing methods to control C-terminal lysine, galactose and sialic acid content in recombinant proteins
    Publication number: 20160237149
    Abstract: Provided herein is a method for producing an antibody, such as an anti-TNF? antibody (e.g., infliximab) having a C-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with DNA encoding the antibody in a culture medium comprising at least 0.5 ?M zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody.
    Type: Application
    Filed: December 23, 2015
    Publication date: August 18, 2016
    Inventors: Marcel Flikweert, Charles Goochee, Francis Maslanka, Franciscus Johannes Ignatius Nagel, James Ryland, Eugene Schaefer
  • MANUFACTURING METHODS TO CONTROL C-TERMINAL LYSINE, GALACTOSE AND SIALIC ACID CONTENT IN RECOMBINANT PROTEINS
    Publication number: 20140273092
    Abstract: Provided herein is a method for producing an antibody, such as an anti-TNF? antibody (e.g., infliximab) having a C-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with DNA encoding the antibody in a culture medium comprising at least 0.5 ?M zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicants: Janssen Biologics B.V., Janssen Biotech, Inc.
    Inventors: Marcel Flikweert, Charles Goochee, Francis Maslanka, Franciscus Johannes Ignatius Nagel, James Ryland, Eugene Schaefer